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Abstract: This paper describes the preliminary results of an ongoing innovation study in Australian 
biotechnology industry. It investigates clustering and the innovation process in selected biotechnology firms 
focusing on major actors and linkages among them. The research was carried out through a survey of 
biotechnology tlrms within the Sydney metropolitan area. Our tlndings suggest that forces external to the 
organisation, such as government regulation, the JP environment, and a lack of suftlcient funds, are among the 
major barriers to the innovation process and commercialisation of innovative products. However, not all 
barriers are entirely external or uncontrollable. Firms in our sample have also reported resource-based barriers 
to innovation such as lack of skilled managers or researchers, lack of physical facilities for research or 
manufacturing, as well as lack of marketing resources or distribution channels. 
Keywords: biotechnology clusters, innovation, linkages, commercialisation, New South Wales (NSW) 
Introduction 
The innovation literature has changed considerably in the past years from an individual approach to a 
systematic view of how large organizations achieve innovation success. It was also widely accepted that large 
organizations have been the main drivers for growth and innovation. More recently, innovation studies has 
shifted to investigating smaller tlrms and networks of tlrms. The purpose of this study is to examine the 
institutional linkages in Australian biotechnology industry. We examine relationships among biotechnology 
tlrms with other research institutions, universities and other partners. Furthermore, barriers to innovation and 
commercialisation in biotechnology and factors influencing performance in Australian biotechnology firms are 
analysed. The paper argues that the nature of the linkages between tlrms, customers, suppliers, distributors, 
agencies, and across sectoral boundaries - influence the scope and purpose of various business activities and 
the innovation process. The nature and characteristics of these linkages often help to determine the 
effectiveness of the innovation process at local, national and international levels. 
The biotechnology sector is comprised of biotechnology tlrms, research institutions, and related 
industrial companies that discover, develop, and commercialise biotechnological; products and processes. 
While the US has the largest and most diverse biotechnology industry, the Australian industry has also grown 
considerably during the past decade. For example, the availability of biotechnology investment capital in 
Australia has improved tremendously. However, Australia's ability to attract and retain top scientists and to 
remain competitive in the biotechnology industry depends on continued support from both government and 
private sources. 
Australian biotechnology tlrms agglomerate in locations with strong technological infrastructure. The 
largest agglomerations in Australia are located in New South Wales (NSW), Victoria ( VlC), and Queensland 
(QLD) ( Fay le, 2000). Taken together, companies in these clusters are responsible tor the bulk of biotechnology 
innovative activity in Australia. State government initiatives are being implemented to strengthen relationships 
between biotechnology industry leaders and university or government research institutions toward the common 
goals of industry cohesion and growth. The three regions of NSW, VIC and QLD have a strong research base, 
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and significant university-industry linkages in place, which promotes infrastructure sharing and 
technology transfer. These relationships have enabled the regional industry to grow and prosper in recent years 
(DSD!, 2004). 
Central to recent innovation studies on regional clusters is the idea that overall innovation performance 
of an economy depends not so much on how specific organisations perform but how well they interact with 
each other (Lundvall, 1992; Nelson 1993). In this perspective the notion of an innovation system has been 
analysed at several levels ranging from sectoral and enterprise specific innovation systems, to local, national, 
regional and global systems of innovation ( Freeman and Soete, 1997; Cooke and Mm·gan, 1998). 
This research contributes to empirical investigation of innovative activities and linkages among a 
cluster of biotechnology firms in Sydney area. It builds on previous research to evaluate the nature of 
connections, linkages and partnerships as key factors in distinguishing clusters (Camagni, 1991; Pmter, 1998; 
Enright, 1998; Cooke and Morgan, 1998; Mitra, 2000). It presents the results obtained from a survey carried 
out in Sydney in 2002. The primary objective of this research is to evaluate the interaction and degree of 
linkage between biotech companies with locally and nationally-based companies, and institutions such as 
customers, suppliers, universities and public research institutions. The methodology also permits some 
evaluation of activities in the innovation process of the firms and their assessment of the suitability of the local 
environment for innovation and commercilisation. The second objective orthis study is to assess both extemal 
and internal barriers to innovation faced by these companies and their impact on innovation success. Before 
presenting the empirical results, a brief introduction to the NS W biotechnology cluster is provided in the next 
section. 
NSW Biotechnology Cluster 
As with other nations, biotechnology R&D is developing in geographic clusters, primarily through the 
proximity of universities, hospitals and medical or agricultural research institutes with essential business and 
financial services (Cooke, 2003). Clustering may be either evolutionary by building on existing local attributes, 
or more formal through planned and purpose built technology parks (e.g. housing designed incubation 
facilities). Porter (2002) has suggested that Australia has groups of companies within the one industry that 
were forming clusters which ultimately create a critical mass that can set a global standard. According to 
Porter, examples of these clusters are horse breeding, wine production, defence technology and biotechnology 
(Porter, 2002).NSW accounts for about 40% of the biotechnology companies in Australia and has 
demonstrated strong research capabilities in pharmaceutical discovery, medical devices and agriculture. In 
Sydney, primarily in recent years, impottant clusters in biotechnology have emerged, combining expertise and 
resources to achieve scientific breakthroughs. The NS W Government is proactive in promoting biotechnology 
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and has provided significant support tor the establishment ofthe Australian Technology Park (ATP) in 
Sydney, a major centre for biotechnology research, as well as other research parks (DSRD, 200 1). The ATP, 
based in central Sydney and supported by three major universities, is a dynamic research campus with a focus 
on biotechnology. Tenants benefit from the location of Johnson & Johnson research on site and purpose-built 
facilities. The A TP operates as an incubator fostering the growth of start-up companies in several fields such as 
biotechnology, photonics, multimedia and advanced interne! services. These companies aim to become 
independent within three years, ready for investment from established venture capital funds. 
The Macquarie University Research Park also provides an interface between the university and 
commercial enterprises. The Australian Proteome Analysis facility and Macquarie Research Ltd, which is the 
licensing and consulting arm of Macquarie University, are also located within the park. Another cluster located 
in the Riverside Corporate Park based on the CSIRO campus in Northern Sydney. In this location, industry 
works closely alongside government researchers in a variety of fields including molecular sciences, food 
sciences, agriculture and mining. Industries also benefit from being close to North Ryde, a major concentration 
of biotech firms. 
In NSW, the largest independent medical research institute is the Gm·van Institute of Medical 
Research. The Gm·van combines laboratory facilities and clinical research capabilities as well as major research 
programs in cancer, arthritis, osteoporosis, diabetes, and mental health. Other major research institutes include 
the Centenary Institute for Cancer Medicine and Biology, the Waiter and Eliza Hall Institute, Australian 
Genomic Research Facility, the Biomolecular Research Institute and the Centre for Drug Design & 
Development. 
Research Context: Innovation and Clusters 
Innovation is critical for biotechnology firms in sustaining their competitive advantage in the industl·y. 
Developing products or processes from scientific breakthroughs and bringing those products to the market is a 
long and costly process, with no guarantees of commercial success. Funding is the lifeblood of biotechnology 
as firms spend millions of dollars on research and development. The innovation process can be quite complex 
because basic research, product development, as well as manufacturing and distribution of a commercial 
product can include several sector players. Strategic alliances and other collaborative agreements among 
universities, biotechnology firms, and larger industrial companies (e.g. pharmaceutical companies) are widely 
used methods of achieving innovation. The ways in which pattner companies combine resources to achieve 
innovation and the key determinants of successful innovation effmts in biotechnology have been the focus of 
recent research (see, for instance, McKelvey, Aim & Riccaboni, 2003; Marsh, 2003). 
For example, knowledge spillovers, inter-firm relationships, utilisation of shared resources, a well­
developed local skills base, and the evolution of the region through tacit and explicit knowledge exchange, are 
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typical features of regional clusters mentioned in the literature ( OECD I 999· Storper I 997· Simmie ' ' ' ' 
and l Sennett, 1999). These features also provide the basis for social and economic 'connectivity' that 
underlines the operation of firms in clusters. 
The definition of clusters as "groups of firms in the same industry, or in closely related industries that 
are in close geographical proximity to each other" is meant to include geographically concentrated industries 
including so-called 'industrial districts' (Enright, I 998:337). The geographic concentration of interconnected 
firms is suppo1ted by interconnected suppliers, downstream channels, customers, manufacturers of 
complementary products, and can also extend to companies with complementary skills (Porter, 1998). Clusters 
also include public institutions, including government education institutions, and support services, with cluster 
boundaries being defined by linkages and complementarities across institutions and industries (Porter, 1998), 
Merging the idea of regional innovation and clusters lies in the understanding of the successful 
evolution of clusters whereby their formation, organisation and structure are themselves features of an 
innovation process. The innovation process in biotechnology has been described as the sequence of activities 
by which an idea is transformed into a commercial product (Rothwell 1994). These activities, in their simplest 
form, consist of research, product development, manufacturing, and marketing. Although this schema implies 
that the innovation process in biotechnology is strictly linear, feedback and interaction among the elements of 
the process are inherent as is true in any indust1y (Kline and Rosenberg, 1986; Malecki, 1997). 
Jt should be noted that not all biotechnology firms attempt to take ideas from the research stage to the 
market Firms may pursue innovation from basic research and discovery and follow through all the way to the 
commercialisation and distribution of a product Conversely, biotechnology firms may specialise in a certain 
phase of the innovation process. Drug discovery companies, for example, operate in the basic research and 
product development stages, licensing their technologies to suitable companies in biotechnology or the 
pharmaceutical industry. In any case, innovation lies at the heart of biotechnology firm strategy, 
The evolution of innovation from the early stages of research to market commercialisation has resulted 
in clusters attracting public and private finance, chambers of commerce and trade associations generating 
commercial market research, regional government providing industry-specific infrastructure, and local 
educational institutions doing industry-specific training and research, This combination of integrated and 
leveraged activity is often at the heart of innovation and collective learning as the literature on innovation 
highlights (Rosenberg, 1982; Malccki, I 997). 
The literature also refers to firms in clusters learning to innovate through a systematic application of 
various competencies and a more productive use of their assets (Mitra, 2000). The learning process is 
continuous and tends to take place even when innovations are not apparent (as in incremental innovations). In 
biotechnology, learning is active and competencies might include: competitive manufacturing; competency in 
marketing, commercialisation and distribution networks; and the ability to deal with the regulatory procedures 
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involved in getting new products onto the market. 
It is often argued that academics, biotechnology firms and large firms bring distinctive advantages to 
the creation of biotechnology innovations. Initially, scientific expertise which lay in the science base, are 
gradually transferred to the biotech firms as they develop their own R&D competences (Cooke, 2003). Large 
firms initially lacked the R&D compelences to innovate in biotechnology themselves, but they had all 
complementary assets necessary to commercialise discoveries, such as manufacturing skills, marketing and 
distribution networks and experience with regulatory processes. These distinctive organisational advantages 
provided the basis for considerable amounts of collaboration and interactions between the different groups. 
The Australian biotechnology industry consists of mostly small and medium-sized firms. Early on, 
small start-ups benefited trom government research funds and infusions of funds from other sources. While 
start-up firms may possess the funding for research and early stages of commercialisation, they often lack the 
necessary testing facilities, manufacturing capabilities nor marketing channels to be successful in launching 
innovation products into the market. It is often difficult for biotechnology firms to attract financing to carry 
them through the entire innovation process. Therefore, a firm may have to combine different sources of capital 
like public funds, venture capital, national research contracts and debt financing to sustain operations (Greis et 
al., 1995). Finally, firm size, government regulation, and funding are all barriers that may have a strong impact 
on the ability of biotechnology firms to becoming innovative and successful in commercialising their products. 
Within this context, our study attempts to identify the main barriers to innovation in selected biotechnology 
firms in the Sydney region. It also argues that the nature of the linkages within the cluster of these biotech 
companies influences the scope and purpose of their various business activities and the innovation process. 
Data and Methodology 
To address the above issues, research was carried out through a survey of firms within the Sydney region of 
N S W. The sample of firms included in the study was drawn ti·om the Australian Biotechnology Directory. 
From a total sampling base of 58 core biotechnology companies in Sydney, a sub-sample of 44 firms was 
chosen to receive questionnaires. The four-page questionnaire was first mailed to 44 biotechnology companies 
in Sydney area. Follow-up telephone calls and emails were also made. ln total sixteen usable responses were 
received, yielding a response rate of 36%. 
A structured questionnaire was designed to map the perceived importance of clusters, linkages, 
financial flow and barriers to innovation and commercialisation within the area. The questions were formulated 
in two different ways: (a) 'factual' questions requiring a dichotomous (yes/no) response; and (b) questions 
which were answered on scale-type responses, indicating intensity of the linkages, location and importance of 
the information and knowledge ranging from little importance to very important. Additionally, follow up 
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discussions held with senior managers of selected firms in order to investigate in more qualitative 
detail the nature of the local cluster and commercialisation process within the firms. 
Table I: Origin of biotech firms 
Origin of Firm (N 16) 
Branch plant 3 
Entrepreneur SMEs 8 
Uni Spin-off 2 
Public R&D Spin-off I 
Corporate Spin-off I 
Incubator Co. I 
Source: Sydney Survey 
Table 1 provides data on origin of the firms. Majority of the firms (8) were formed by an entrepreneur 
as a small business and out of 16 firms only 4 firms were spin-offs either from a university or a public research 
centre. As an example, in one case the University of Macquarie has served as an incubator for a new 
biotechnology firm, providing researchers with the resources necessary to commercialise scientific discoveries. 
Industrial spin-off accounted for only 1 firm out of respondents. 
Institutional Linkages 
This section examines the relationship between these biotechnology firms and institutional linkages 
with other organizations. We were particularly interested in asking the following questions: Which partners do 
firms interact with in the innovation process? How important are these interactions? and where are those firms 
located? We can see from Table 2 below that there are strong interactions between these firms, universities and 
their customers. This is consistent with other literature findings asserting that innovation in biotechnology 
firms often takes place interactively with major research universities (Kline and Rosenberg, 1 986; Dosi, 1998). 




Customers 3 3 
Suppliers 3 3 
Foreign partners I 7 
Consultants 5 2 
Public R&D Centres 4 4 
Private Research Institutes 5 5 
Hospitals 5 6 
Other firms 4 2 
Venture Capital firms 9 4 
Note: O�Never, J�Seldom, 2�Frequently, 3-Aiways 














Alwavs Mean Rank 
2 1.87 1 
6 1.81 2 
5 1.56 3 
2 1.56 3 
I 1.31 4 
I 1.31 4 
I 1.12 5 
2 1.12 5 
2 LI2 5 
0.62 6 
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Customers frequently provide ideas for product development and modifications as well as for new 
products and they may contribute substantially to the design and development process. In the case of medical 
instruments, for example, suppliers were reported the trigger of innovation, through the provision of better 
performing components or new materials. Also they often contribute to the required process technology. 
Frequently these relations are not of the market type (short term) but interactive and more durable (network). 
Interestingly, customers and suppliers as innovation partners are not confined to the region but for our 
sample of the firms more frequently located at the national and even global level. While a few firms indicated 
that their customers are local, the majority of them have customers located outside the local region of Sydney 
and otlen have international customers. 
Links with public research providers such as public R&D centres were also reported to be strong 
especially with CSIRO centres in Sydney area. This 'strong relationship', however, was not the case with 
venture capitals firms. It was rather surprising to find that there was relatively little mention of venture capital 
firms as innovation pattners. Partly this may be because the services of these institutions are regarded as being 
not tailored to the real needs of these firms. While venture capital firms are becoming more common and 
gaining increasing relevance with Australian biotechnology industry, use of these entities still appears to be 
limited, although there is evidence of increasing use among SMEs in high-tech sectors. 
Consultants, however, seem to play a relatively important role in the commercilisation process of these 
companies. They provide know-how in various relevant fields, from legal aspects of patenting and licensing to 
consulting with respect to technology-access, innovation management and marketing/distribution. Due to the 
specialised nature of the required knowledge, they are not only drawn from the local region but from the 
national level as well. 
Foreign partners or other firms seem to have a notable relevance as being other potential partners. 
Interestingly, there was a significant degree of contact between companies with foreign pmtners, but also 
between companies within the same or different industry sectors. Out of 16 firms 6 companies reported that 
they had either frequent or constant contact with companies from other countries, with only I reporting no 
contact. Also, 8 firms repmted either frequent or constant contact with firms within the same or other industry 
sector, with 4 firms reporting no interaction. 
On the whole, the results together with comments by interviewees, suggest that there is significant 
contact and collaboration between these biotechnology firms and other institutions whether being a research 
centre in a university setting or a public R&D centre. 
Commercialisation Hurdles 
Australian universities and public research institutions are increasingly active in promoting the 
commercialisation of intellectual property. Most NS W universities and government research institutions have a 
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specialised commercialisation unit or incorporated arms for managing the commercialisation of 
research outcomes. For example, Unisearch Limited, which is the commercial arm of Sydney's University of 
New South Wales (UNS W), is the most active technology commercialisation company in Australia with a 
portfolio of over 250 patents, 30 existing licence agreements and equity interests in four technology spin-off 
companies. 
In line with the increase in technology transfer and commercialisation activity of these institutions, the 
number of start-ups has risen considerably with a record 45 firms formed in the 2000/2001 financial year 
( Hopper & Thorburn, 200 l ). The data also indicates that research institutions have been more accepting of 
spin-offs as a technology transfer tool. A growing propot1ion of biotech firms are spin-offs from research 
institutions. According to a recent report ( Hopper & Thorburn, 200 1 ), the proportion of spin-offs hit almost 
70% of all new start-ups and the overall trend is 58% over the last five years. 
According to another Biotechnology Report (Ernst & Young, 200 1) most of the companies that have 
been surveyed are developing technology from their founders or in-licensed from universities and the CSlRO. 
On the basis of this repot1, almost half of Australia's biotechnology companies have been created to 
commercialise inventions and discoveries of one or more of their founders rather than by in-licensing new 
technologies. However, the report indicates a healthy diversity of sources of new business ideas as many 
companies are also active in licensing from universities and the CSIRO. 
Given the fact that most of the Australian biotechnology industry consists of mostly small and 
medium-sized firm, we were interested in identifying barriers to success of these smaller firms. We asked our 
respondents to indicate potential barriers and their significance to innovation and commercialisation (Table 3). 
The most significant barrier reported in our sample of firms was lack of funds. These results seem reasonable 
considering that product sales consist of the main sources of R&D funding for new established firms operating 
in earlier-stage of innovation. Therefore, the judicious use of limited resources is crucial to the success of their 
innovation process. The issue off unding for new established firms is also high on the agenda of the State's and 
Federal's biotechnology initiative (Biotechnology Australia, 2000). 
Personal interviews with managers indicated that the Australian regulatory process is also one of the 
greatest barriers to innovation and commercialisation. Lack of qualified personnel and a lack of manufacturing 
facilities report significantly high by the Sydney firms. Another barrier to innovation repot1ed by firms is lack 
of skilled managers. These tindings support earlier reports about Australian biotechnology industry asserting 
that the major obstacles to product development and commercialisation included difficulty raising funding or 
insufficient funding, heavy government regulation or a long approval process, and a lack of qualified 
managers. 
Table 3 
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Barriers to commercialisation (N=l6) Number of Firms 
Excessive perceived economic risks 6 
Costs too high 10 
Lack of appropriate sources of finance 9 
Organisational rigidities 2 
Lack of qualified personnel 8 
Lack of information on markets 5 
Fulfilling regulations, standards 8 
Source: Sydney Survey 
Note: Mu ltiple choices allowed 
Other findings in our study suggest that collaboration with universities or research centres were 
important factors in explaining firm's performance. Reports by respondents indicate that forces external to the 
organisation were among the main barriers to their innovation. These included, government regulation, 
intellectual property regime, and a lack of government research funds. Collaboration with universities, research 
centres and industrial companies was rated more important than collaboration with other biotechnology firms. 
In an industry where collaboration is prevalent, it may be expected that as the Australian industry matures, 
collaboration may play an even more impmtant role in firm performance. 
However, not all barriers are entirely external or uncontrollable. Many firms reported resource-based 
barriers to innovation such as lack of skilled managers or researchers, lack of physical facilities for research or 
manufacturing, as well as lack of marketing or distribution channels. In fact, the most significant factors to 
which firms attributed their innovation performance were internal rather than external. Product quality, speed 
of product development, the ability to reorganise the commercial applicability of technology and firms' 
managerial skills were among the highest-rated factors. 
Personal interviews with several managers from sample firms support the above findings. For example, 
one of the questions asked was if (innovation in their firms was driven by scientific breakthrough or by market 
demand or need). Managers for the most pati maintained that innovation is initially s cience-driven, and for 
some firms this was a disadvantage because they had no products ready for market launch. Firms with products 
on the market maintained that while s cientifi c  advances were the cornerstone of innovations, the projects that 
received funding and approval to move ahead with marketing activities were more successful in getting their 
products ready for market launch, for example diagnostic tests for a specific disease, or a therapy for known 
disease. 
Discussion and Conclusion 
In the context of a more systematic innovation approach this study investigated how innovative activities of 
biotechnology firms are organised and the importance of linkages with other industry agents. We have 
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presented our initial results trom a survey of biotechnology firms in the Sydney area of New South Wales 
(NSW). In meeting the first objective of this study we explored the benefits of innovation and 
commercialisation through clustering and a process of innovation management to build on the advantages of 
new technology and innovation. 
Our results indicate that biotechnology firms which regularly carry out R&D through collaboration and 
networking achieve higher average rates of turnover and make a greater contribution towards providing 
employment. The findings, however, also suggest that not only horizontal partnerships with research 
institutions and universities cooperation plays a distinctly important role in innovation linkages of the sample 
firms, but also vertical relationships with suppliers and customers seem important for these firms. 
As for the importance of locality, it appears that the regional range of innovative linkages is focused 
primarily on national levels. While linkages with customers and suppliers are very intensive with partners 
across Australia and overseas, collaboration with universities and training institutions often takes place in the 
closer vicinity. This is probably due to the tacit character of knowledge transfer between these pminers, where 
face-to-face contacts are a prerequisite for joint innovation projects. These findings suggest that while these 
firms operate within a local cluster, substantial links exist to suppliers and customers outside the region. This is 
particularly true for more innovative firms, which extend their operation nationally and globally. 
Overall, the necessity to link and network with outside organisations seems to be essential for our 
sample group. For the larger companies, which have resources, experience, capital backing and established 
reputation, these connections are relatively straightforward and common-place practice. In fact, they have 
become integral to the way business is conducted. However, the smaller companies still lack the benefits of 
institutional linkages and need to futiher develop their connections with universities, venture capital firms, 
public research organisations, funding agencies and training establishments. Local competencies in research 
institutions or knowledge services can be an important source of innovation activities for these smaller firms. 
These institutions could play a far more impotiant role than they do at present. However, as our research 
suggest, biotechnology firms tend to make use more of locally trained skilled staff in their business and focus 
on innovative activities rather than rely on other forms of collaboration. 
In sum, by studying the examples of clustering, both regional policy makers and firm managers can 
make decisions, which are aimed at improving the innovation process and competitiveness capabilities. In 
forming effective policies both at the level of the firm and the region, decision makers may need to consider 
the learning process inherent in the management of externalities and internalities, especially in dealing with 
uncertainty and complexity. 
Ensuring effective technological connectivity coupled with appropriate management know-how is 
perhaps essential for these high-tech firms. It may, enable them to better connect, particularly in their 
knowledge base, learning processes and competencies, with their business environment. Also, from a policy 
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development point of view it is critical to understand the evolutionary stages of innovation in the firm 
as well as the cluster in which the firm is located. Of equal value, is the recognition of the each stage in the 
evolutionary process that offers its own opportunities for managing innovation both at the level of the firm and 
the cluster. 
Finally, it is important to consider the main critical factors of innovation success in the context of 
institutional linkages and cluster theory. In fact, although clusters are highly individual and differentiated, it is 
helpful to identify some common factors of success and, in particular, their innovative capability, linked to 
continuous learning at level of single firm and at the level of the systems of !inns which refer to collective 
learning and learning by interacting. 
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